drugset / Trial / NCT03276988

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

NCT03276988

Phase 1/2 Completed 8 enrolled Genexine, Inc. Symyoo · collab
RandomizedCrossoverDouble-blindDiagnostic

Summary

This study is designed as a combination of phase 1 (Part A) and phase 2 (Part B). The purpose of Part A was to determine the safety, tolerability, and pharmacokinetics in patients with total thyroidectomy or near total thyroidectomy of GX-30 and it has been completed. The Part B is currently recruiting and will investigate the efficacy and safety of GX-30 compared with THYROGEN®.

Timeline

Start
2017-09-07
Primary completion
2020-01-20
Completion
2020-01-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject rhTSH Protein / enzyme biologic 0.9 mg Intramuscular